Albert Bourla, Pfizer CEO (Gian Ehrenzeller/Keystone via AP Images)
In another PhIII, Albert Bourla continues to build case for a once-flopped GHD drug
A growth hormone treatment that’s seen a turbulent path may finally be reaching the light at the end of the tunnel.
Pfizer and Opko Health …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
